News und Analysen

Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biopharmaceutical company focusing on immunology and oncology drug development, reported its latest financial results on August 7, 2025, for the

Coherus Oncology (NASDAQ:CHRS), a biotechnology company focused on developing and commercializing innovative immuno-oncology therapies, reported earnings for Q2 2025 on August 7, 2025. The results

CytomX Therapeutics (NASDAQ:CTMX), a biotechnology company focused on developing targeted oncology therapies, reported its second quarter 2025 results on August 7, 2025. In the period, the most

Organogenesis (NASDAQ:ORGO), a regenerative medicine company specializing in advanced wound care and surgical and sports medicine products, reported Q2 2025 results on August 7, 2025. The standout

Dynavax Technologies (NASDAQ:DVAX), a biotechnology company focused on vaccines, released its results for the second quarter of 2025 on August 7, 2025. The company posted GAAP revenue of $95.4

Cidara Therapeutics (NASDAQ:CDTX), a biotechnology company focused on the development of innovative therapies for infectious diseases and oncology, released its second-quarter 2025 earnings on

Cytokinetics (NASDAQ:CYTK), a late-stage biopharmaceutical company focused on cardiovascular disease, reported earnings for Q2 FY2025 on August 7, 2025. The headline news was a dramatic

Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies, released its earnings results for Q2 2025 on August 7, 2025

Intellia Therapeutics (NASDAQ:NTLA), a biotechnology company developing CRISPR-based gene-editing therapies, reported second quarter 2025 results on August 7, 2025. The headline news was a

Dentsply Sirona (NASDAQ:XRAY), a major player in dental products and technologies, released its second quarter results on August 7, 2025. The company reported GAAP revenue of $936 million and

Avadel Pharmaceuticals Plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to improve lives, released its earnings for Q2 2025 on August 7, 2025. The headline news is

Akebia Therapeutics (NASDAQ:AKBA), a biopharmaceutical company specializing in kidney disease treatments, reported its earnings on August 7, 2025, covering results for the quarter. The headline news

Immunic (NASDAQ:IMUX), a late-stage biotechnology company focused on autoimmune and inflammatory diseases, released its second quarter 2025 results on August 7, 2025. The quarter was marked by

Ecovyst (NYSE:ECVT), a specialty catalyst and chemicals provider focused on industrial and environmental markets, released its second-quarter 2025 results on August 7, 2025. The main headlines: the

Incoming patent cliffs regarding some of Pfizer's (NYSE: PFE) largest revenue streams have been pressuring the pharmaceutical stock. The price is down, but its dividend payout keeps rising. Last

Veracyte (NASDAQ:VCYT), a leader in advanced cancer diagnostics, reported results for Q2 2025 on August 6, 2025. The headline news: the company outperformed expectations on both revenue and

CareDx (NASDAQ:CDNA), a molecular diagnostics company specializing in transplant care solutions, released its results for the second quarter of fiscal 2025 on August 6, 2025. The big news from the

Innoviva (NASDAQ:INVA), a pharmaceutical company specializing in royalties and specialty therapeutics, reported second-quarter earnings on August 6, 2025. The company announced earnings per share

Orion (NYSE:OEC), a leading global producer of carbon black, reported its second quarter results on August 6, 2025. The most notable news was that GAAP revenue came in at $466.4 million for Q2 2025

Pulmatrix (NASDAQ:PULM), a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that

Seres Therapeutics (NASDAQ:MCRB), a clinical-stage biotech focused on microbiome therapeutics, released its second quarter 2025 earnings on August 6, 2025. The main highlight was a narrowing net

AnaptysBio (NASDAQ:ANAB), a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, released its Q2 2025 earnings on August 6

Royalty Pharma Plc (NASDAQ:RPRX), a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts—its

BeOne Medicines (NASDAQ:ONC), a global oncology-focused pharmaceutical company, released results for Q2 2025 on August 6, 2025. The most notable news was a sustained acceleration across revenue

Novavax (NASDAQ:NVAX), known for its protein-based vaccine technology, released its second quarter fiscal 2025 results on August 6, 2025. The standout news was a return to profitability on a GAAP